WASHINGTON (AP) - A huge study of another COVID-19 vaccine candidate is getting underway Monday as states in the U.S.
continue to roll out scarce supplies of the nation’s first shot options.The U.S. has authorized emergency use of two vaccines, one made by Pfizer and BioNTech and the other by Moderna, but doses will be rationed for months.The candidate made by Novavax Inc.
is the fifth to reach final-stage testing in the U.S. Some 30,000 volunteers are needed to prove if this vaccine — a different kind than its Pfizer and Moderna competitors — really works and is safe.RELATED: Volunteers still needed to test variety of coronavirus vaccinesThe study, which is funded by the U.S.